1. Home
  2. ALLO vs ARQQ Comparison

ALLO vs ARQQ Comparison

Compare ALLO & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • ARQQ
  • Stock Information
  • Founded
  • ALLO 2017
  • ARQQ 2017
  • Country
  • ALLO United States
  • ARQQ United Kingdom
  • Employees
  • ALLO N/A
  • ARQQ N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • ARQQ Computer Software: Prepackaged Software
  • Sector
  • ALLO Health Care
  • ARQQ Technology
  • Exchange
  • ALLO Nasdaq
  • ARQQ Nasdaq
  • Market Cap
  • ALLO 277.8M
  • ARQQ 309.4M
  • IPO Year
  • ALLO 2018
  • ARQQ N/A
  • Fundamental
  • Price
  • ALLO $1.40
  • ARQQ $26.72
  • Analyst Decision
  • ALLO Strong Buy
  • ARQQ Strong Buy
  • Analyst Count
  • ALLO 9
  • ARQQ 1
  • Target Price
  • ALLO $8.44
  • ARQQ $52.00
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • ARQQ 1.4M
  • Earning Date
  • ALLO 08-06-2025
  • ARQQ 05-22-2025
  • Dividend Yield
  • ALLO N/A
  • ARQQ N/A
  • EPS Growth
  • ALLO N/A
  • ARQQ N/A
  • EPS
  • ALLO N/A
  • ARQQ 0.48
  • Revenue
  • ALLO N/A
  • ARQQ $241,000.00
  • Revenue This Year
  • ALLO N/A
  • ARQQ $1,818.77
  • Revenue Next Year
  • ALLO N/A
  • ARQQ N/A
  • P/E Ratio
  • ALLO N/A
  • ARQQ $54.89
  • Revenue Growth
  • ALLO N/A
  • ARQQ N/A
  • 52 Week Low
  • ALLO $0.86
  • ARQQ $3.72
  • 52 Week High
  • ALLO $3.78
  • ARQQ $52.79
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 56.45
  • ARQQ 62.99
  • Support Level
  • ALLO $1.27
  • ARQQ $24.30
  • Resistance Level
  • ALLO $1.51
  • ARQQ $28.44
  • Average True Range (ATR)
  • ALLO 0.11
  • ARQQ 2.88
  • MACD
  • ALLO 0.04
  • ARQQ 0.11
  • Stochastic Oscillator
  • ALLO 77.55
  • ARQQ 49.48

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About ARQQ Arqit Quantum Inc.

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.

Share on Social Networks: